Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-12-186415
Filing Date
2012-04-26
Accepted
2012-04-26 17:07:52
Documents
3
Effectiveness Date
2012-04-26

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d341174d8k.htm DEFA14A 25986
2 BY-LAWS OF NABI BIOPHARMACEUTICALS d341174dex31.htm EX-3.1 84689
3 FIRST AMENDMENT TO RIGHTS AGREEMENT d341174dex41.htm EX-4.1 9043
  Complete submission text file 0001193125-12-186415.txt   121006
Mailing Address 12270 WILKINS AVENUE ROCKVILLE MD 20852
Business Address 12270 WILKINS AVENUE ROCKVILLE MD 20852 301-770-3099
NABI BIOPHARMACEUTICALS (Filer) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 1226
Type: DEFA14A | Act: 34 | File No.: 001-35285 | Film No.: 12784453
SIC: 2836 Biological Products, (No Diagnostic Substances)